2020
DOI: 10.1016/j.vhri.2019.07.002
|View full text |Cite
|
Sign up to set email alerts
|

The Economic Burden of Candidemia and Invasive Candidiasis: A Systematic Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
40
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(40 citation statements)
references
References 12 publications
0
40
0
Order By: Relevance
“…Candidemia is the most common form of invasive candidiasis, and is known to be the fourth to seventh most common bloodstream infection [1]. It is often associated with a high mortality rate of approximately 40-60% and a significant economic burden [2][3][4][5]. Due to the growing number of immunocompromised patients and critically ill patients, as well as the increasing use of invasive devices and antibiotics, the incidence of candidemia has been increasing around the world [2,6].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Candidemia is the most common form of invasive candidiasis, and is known to be the fourth to seventh most common bloodstream infection [1]. It is often associated with a high mortality rate of approximately 40-60% and a significant economic burden [2][3][4][5]. Due to the growing number of immunocompromised patients and critically ill patients, as well as the increasing use of invasive devices and antibiotics, the incidence of candidemia has been increasing around the world [2,6].…”
Section: Introductionmentioning
confidence: 99%
“…It is often associated with a high mortality rate of approximately 40-60% and a significant economic burden [2][3][4][5]. Due to the growing number of immunocompromised patients and critically ill patients, as well as the increasing use of invasive devices and antibiotics, the incidence of candidemia has been increasing around the world [2,6]. Particularly, there has been a rise in the incidence of non-albicans candidemia (NAC) [7].…”
Section: Introductionmentioning
confidence: 99%
“… 18 Invasive forms of Candida BSIs have been associated with significant costs (about $160 000 per patient) and healthcare use. 19 , 20 They are also associated with high mortalities, which reportedly range between 35% and 71%, 8 , 21 - 25 and could be exacerbated when empirical antifungal therapy is delayed. 26 - 28 …”
Section: Clinical Significance Of and Possible Aetiological Shift In Candida Bsismentioning
confidence: 99%
“…Mortality rates among patients range from 19.6% to 67% worldwide, but the exact rate of candidaemia is underestimated due to the difficulty and delay in diagnosis, which leads to prolonged hospitalisation and financial burden on the healthcare system. 16,17 Although non-albicans Candida species have been increasingly reported, C .albicans is still the leading cause of invasive Candida infections. 8,[18][19][20] As Candida exposure is ubiquitous, there has been a development of universal prophylaxis strategies for high-risk patients.…”
Section: Introductionmentioning
confidence: 99%